Research analysts who have asked questions during Grifols earnings calls.
GS
Guilherme Sampaio
CaixaBank, S.A.
4 questions for GRFS
JE
Jaime Escribano
Banco Santander, S.A.
4 questions for GRFS
Also covers: GRF
AL
Alvaro Lenze Julia
Alantra Equities
3 questions for GRFS
CP
Charles Pitman
Barclays PLC
3 questions for GRFS
Also covers: ARGX, SOAGY
Graham Parry
Bank of America Corporation
2 questions for GRFS
Also covers: AZN, GSK, NVS +1 more
JG
James Gordon
JPMorgan Chase & Co.
2 questions for GRFS
Also covers: ARGX, AZN, GMAB +4 more
Joaquin Garcia-Quiros
JB Capital
2 questions for GRFS
Thibault Boutherin
Morgan Stanley
2 questions for GRFS
Also covers: ALVO, EVO, INDV +2 more
TJ
Thomas Jones
Berenberg
2 questions for GRFS
ÁL
Álvaro Lenze
Alantra Equities
1 question for GRFS
Also covers: FER, GRF
AL
Alvaro Lenze Julia
Alantra
1 question for GRFS
CP
Charles Pitman-King
Barclays
1 question for GRFS
Also covers: ARGX
PV
Peter Verdult
Citigroup Inc.
1 question for GRFS
Also covers: AZN, EVO, GMAB +4 more
Recent press releases and 8-K filings for GRFS.
Grifols Reports Strong FY 2025 Financial Results
GRFS
Earnings
Guidance Update
Product Launch
- Grifols reported FY 2025 revenues of EUR 7,524 million, an increase of 7.0% at constant currency, primarily driven by the Biopharma business.
- The company's Group profit more than doubled to EUR 402 million in 2025, marking a 156.1% increase from EUR 157 million in 2024.
- Adjusted EBITDA reached EUR 1,825 million, growing 5.6% at constant currency, with an adjusted EBITDA margin of 24.3%.
- Free Cash Flow pre-M&A significantly improved to EUR 468 million, an increase of EUR 201 million compared to 2024.
- The leverage ratio declined from 4.6x in 2024 to 4.2x in 2025, demonstrating continued deleveraging progress.
1 day ago
Grifols, S.A. Reports Profit Turnaround and Increased Income in Q4 2025
GRFS
Earnings
Debt Issuance
Dividends
- Grifols, S.A. reported a profit for the year of €192,054 thousand in 2025, a significant improvement from a loss of €83,138 thousand in 2024.
- The company's total income increased to €1,228,224 thousand in 2025 from €700,563 thousand in 2024, primarily driven by a substantial increase in dividends received (€400,633 thousand in 2025 vs. €7,409 thousand in 2024) and financial income (€548,322 thousand in 2025 vs. €445,825 thousand in 2024).
- As of December 31, 2025, total equity was €1,973,131 thousand, while total non-current liabilities stood at €10,350,821 thousand and total current liabilities were €331,807 thousand.
- The company's non-current financial liabilities include promissory notes of €5,316,785 thousand and loans and borrowings of €878,368 thousand as of December 31, 2025. Additionally, a €500 million loan granted to Grifols Worldwide Operations Ltd was capitalized as an increase in financial investment during 2025.
1 day ago
Grifols reports Q3 2025 financial results
GRFS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Grifols reported Q3 2025 revenues of EUR 1,865 million, an increase of 9.1% at constant currency (cc) year-over-year, and Adjusted EBITDA of EUR 482 million, an 8.8% cc increase with a 25.8% margin.
- Year-to-date Q3 2025 revenues reached EUR 5,542 million (up 7.7% cc) and Adjusted EBITDA was EUR 1,358 million (up 11.2% cc) with a 24.5% margin.
- Group profit for Q3 2025 was EUR 127 million (up 146%), contributing to a year-to-date profit of EUR 304 million (up 245%).
- The company generated EUR 203 million in free cash flow pre-M&A pre-dividend in Q3 2025, with the year-to-date total at EUR 188 million, an improvement of EUR 257 million year-over-year.
- The leverage ratio improved to 4.2x from 5.1x in the prior year, with liquidity at EUR 1,475 million. Grifols also improved its full-year revenue and free cash flow pre-M&A pre-dividends guidance while maintaining its Adjusted EBITDA guidance.
Nov 4, 2025, 6:03 PM
Grifols Reports Strong Q3 2025 Results and Updates Guidance
GRFS
Earnings
Guidance Update
Product Launch
- Grifols reported Q3 2025 net revenues of €1.87 billion, up 9.1% year-over-year on a constant currency basis, and year-to-date adjusted EBITDA of €1,358 million, an 11.2% increase. Free cash flow pre-M&A and pre-dividends significantly improved by €257 million year-over-year to €188 million year-to-date.
- The company reaffirmed its full-year 2025 revenue and Adjusted EBITDA guidance and updated its free cash flow guidance to more than €400 million. The leverage ratio as per credit agreement improved to 4.2 times at the end of Q3.
- The Immunoglobulins franchise led growth with 18% in Q3 and 14% year-to-date at constant currency. The US launch of Fibrinogen for Congenital Fibrinogen Deficiency is anticipated in H1 2026, with an FDA decision expected in late December.
Nov 4, 2025, 5:30 PM
Grifols announces strong H1 2025 results
GRFS
Earnings
Guidance Update
Dividends
- Grifols reported H1 2025 revenues of EUR 3,677 million, a 7.0% increase at constant currency, and a net profit of EUR 177 million, nearly four times the figure reported in H1 2024.
- The company's adjusted EBITDA rose 12.7% at constant currency to EUR 876 million, achieving a 23.8% margin.
- Free cash flow pre-M&A improved by EUR 182 million year-on-year, resulting in minus EUR 14 million for H1 2025, and the leverage ratio decreased to 4.2x from 5.5x in H1 2024.
- Grifols reinstated a dividend payment of EUR 0.15 per share and reaffirmed its 2025 guidance, improving the Free Cash Flow pre-M&A guidance to EUR 375-425 million.
Jul 30, 2025, 12:00 AM
Grifols completes delisting offer for Biotest shares
GRFS
M&A
Delisting/Listing Issues
- Grifols Biotest Holdings launched a public delisting offer for Biotest at €43.00 per ordinary share and €30.00 per preferred share, with the acceptance period ending on June 6, 2025.
- The offer was accepted for 416,922 ordinary shares (≈2.11% of voting shares; ≈1.05% of share capital) and 3,002,804 preferred shares (≈15.18% of preferred shares; ≈7.59% of share capital), totaling €108,011,766 in payouts.
- Post-offer, Grifols holds 99.25% of voting ordinary shares and 61.40% of non-voting preferred shares of Biotest, directly and via its subsidiary.
- Biotest shares were delisted from the Frankfurt Stock Exchange effective June 6, 2025, with settlement expected by June 16, 2025.
Jun 12, 2025, 12:00 AM
Grifols SA Approves Board Restructuring Proposals
GRFS
Board Change
- The Ordinary General Shareholders' Meeting on June 5, 2025, approved key proposals, including board restructuring and approval of resolutions.
- The Board of Directors appointed Mrs. Anne-Catherine Berner as the new Chairperson and reorganized several committees, indicating significant governance changes.
Jun 5, 2025, 12:00 AM
Grifols SA Publishes 6-K on Biotest Delisting Offer
GRFS
M&A
Delisting/Listing Issues
- Grifols SA released a Form 6-K on May 6, 2025, providing inside information regarding its subsidiary's offer document approval.
- The report announces that BaFin approved the offer for a public delisting purchase of Biotest AG’s shares.
- The offer proposes EUR 43.00 per ordinary share and EUR 30.00 per preference share, with an acceptance period from May 6 until June 6, 2025.
May 6, 2025, 12:00 AM
Grifols SA Reports Potential New Share Offer Discussion
GRFS
M&A
- The document is a Form 6-K from Grifols SA, published in April 2025, outlining that the board has no knowledge of media reports regarding a potential new offer for its shares by Brookfield Capital Partners (UK) Limited.
- The report was officially signed by Authorized Signatory David I. Bell, confirming the company's position on the matter.
Apr 2, 2025, 12:00 AM
Grifols Initiates Public Delisting Offer for Biotest
GRFS
Delisting/Listing Issues
Takeover Bid
- Grifols announces that its subsidiary, Grifols Biotest Holdings GmbH, will submit a public delisting purchase offer for all no-par bearer common shares and non-voting bearer preferred shares of Biotest AG at EUR 43 and EUR 30 respectively.
- The offer is part of an effort to cancel Biotest's trading on the Frankfurt Securities Exchange, with the final steps dependent on the approval of the offer document by BaFin.
- The Board of Directors unanimously approved this move, with the inside information disclosed on March 31, 2025.
Mar 31, 2025, 12:00 AM
Quarterly earnings call transcripts for Grifols.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more